26,260 Shares in Revvity, Inc. (NYSE:RVTY) Purchased by Handelsbanken Fonder AB

Handelsbanken Fonder AB acquired a new position in Revvity, Inc. (NYSE:RVTY - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 26,260 shares of the company's stock, valued at approximately $2,870,000.

Several other institutional investors and hedge funds have also bought and sold shares of the business. CWM LLC purchased a new stake in Revvity in the 4th quarter worth approximately $251,000. Sumitomo Mitsui DS Asset Management Company Ltd purchased a new position in shares of Revvity in the 4th quarter valued at approximately $1,358,000. Signaturefd LLC purchased a new position in shares of Revvity in the 4th quarter valued at approximately $211,000. Lindbrook Capital LLC purchased a new position in shares of Revvity in the 4th quarter valued at approximately $47,000. Finally, abrdn plc purchased a new position in shares of Revvity in the 4th quarter valued at approximately $5,751,000. Hedge funds and other institutional investors own 86.65% of the company's stock.

Revvity Trading Down 0.6 %

NYSE RVTY traded down $0.58 during trading hours on Friday, hitting $101.51. 827,386 shares of the company were exchanged, compared to its average volume of 939,494. The stock has a 50-day moving average price of $104.66 and a 200 day moving average price of $101.40. The company has a quick ratio of 1.77, a current ratio of 2.07 and a debt-to-equity ratio of 0.40. Revvity, Inc. has a 52 week low of $79.50 and a 52 week high of $132.54. The stock has a market cap of $12.54 billion, a PE ratio of 18.46, a price-to-earnings-growth ratio of 2.66 and a beta of 1.09.

Revvity (NYSE:RVTY - Get Free Report) last released its earnings results on Thursday, February 1st. The company reported $1.25 EPS for the quarter, beating analysts' consensus estimates of $1.15 by $0.10. The firm had revenue of $695.90 million for the quarter. Revvity had a return on equity of 7.41% and a net margin of 25.20%. Analysts forecast that Revvity, Inc. will post 4.65 earnings per share for the current fiscal year.

Revvity Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 9th. Investors of record on Friday, July 19th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Friday, July 19th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.28%. Revvity's payout ratio is 5.09%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on RVTY. KeyCorp raised their target price on Revvity from $110.00 to $126.00 and gave the company an "overweight" rating in a research note on Friday, February 2nd. Evercore ISI upgraded Revvity from an "in-line" rating to an "outperform" rating and raised their target price for the company from $88.00 to $125.00 in a research note on Thursday, January 4th. Raymond James raised their target price on Revvity from $106.00 to $127.00 and gave the company an "outperform" rating in a research note on Friday, February 2nd. Barclays raised their target price on Revvity from $92.00 to $105.00 and gave the company an "equal weight" rating in a research note on Thursday, January 25th. Finally, UBS Group lowered Revvity from a "buy" rating to a "neutral" rating and raised their price objective for the company from $105.00 to $125.00 in a research report on Tuesday, January 16th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $118.91.

Insider Activity at Revvity

In related news, insider Prahlad R. Singh sold 21,217 shares of the business's stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $104.28, for a total value of $2,212,508.76. Following the completion of the sale, the insider now owns 92,801 shares in the company, valued at $9,677,288.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.60% of the stock is owned by company insiders.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.